outcomes of non-intensive chemotherapy differ for idh1 and idh2-mutated aml
Published 5 months ago • 78 plays • Length 1:16Download video MP4
Download video MP3
Similar videos
-
1:53
treatment strategies for patients with idh1/2-mutated aml ineligible for intensive chemotherapy
-
2:00
flt3-itd-specific mrd predicts outcomes of chemotherapy in aml
-
1:22
unanswered questions in aml: classification, the role of chemotherapy & avoiding relapse
-
3:55
ziftomenib: a menin inhibitor for r/r npm1-mutated aml
-
5:01
novel classification system to improve post-transplant aml prognosis
-
3:03
improving aml outcomes
-
2:22
session highlights: idh inhibitors, salvage regimens, and other novel developments in aml
-
1:10
novel methods to assess the effectiveness of chemotherapy in aml patients: mrd
-
9:38
pathology-acute myeloid leukemia | aml made easy | clinical features and diagnosis #acuteleukemias
-
9:40
acute myeloid leukemia outcomes
-
2:19
acute myeloid leukemia - causes, symptoms, treatments & more…
-
1:39
optimizing chemotherapy in aml
-
2:34
the evolution of the aml treatment paradigm
-
3:44
aml: novel conditioning and maintenance strategies
-
1:01
novel treatment paradigms for aml at ash 2021
-
4:31
limitations of targeted therapy for aml
-
2:44
phase i/ii study of novel flt3 inhibitor hm43239 in r/r aml
-
3:14
determining the optimal frontline treatment of aml
-
2:28
is high dose chemotherapy still as important in aml?
-
1:40
intensive chemotherapy for aml: do we still need it?
-
3:37
the future of aml treatment
-
1:38
cytogenetic risk stratification in flt3-mt npm1-negative aml undergoing allosct in remission